These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21447724)

  • 1. Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake.
    Brogsitter C; Faulhaber D; Kotzerke J
    Clin Cancer Res; 2011 Apr; 17(7):2065. PubMed ID: 21447724
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
    Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
    Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis.
    Sänger P; Schierz JH; Marlowe RJ; Freesmeyer M
    Liver Int; 2014 Jan; 34(1):161. PubMed ID: 23663248
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraarterial Peptide Receptor Radionuclide Therapy Using
    Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
    J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors.
    Kratochwil C; Giesel FL; López-Benítez R; Schimpfky N; Kunze K; Eisenhut M; Kauczor HU; Haberkorn U
    Clin Cancer Res; 2010 May; 16(10):2899-905. PubMed ID: 20460485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parametric Net Influx Rate Images of
    Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
    J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
    [No Abstract]   [Full Text] [Related]  

  • 11. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
    Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
    Giesel FL; Wulfert S; Zechmann CM; Haberkorn U; Kratochwil C; Flechsig P; Kuder T; Schwartz LH; Bruchertseifer F
    Exp Oncol; 2013 Jun; 35(2):122-6. PubMed ID: 23828389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
    Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
    Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
    Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
    Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
    Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
    Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
    Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radioisotope therapy with somatostatin analogues in neuroendocrine tumours (case report)].
    Kunikowska J; Królicki L; Cwikła J; Mikołajczak R; Pawlak D; Korsak A; Kozłowicz I; Poprawski J; Płazińska M; Kobylecka M; Maczewska J; Zycińska K; Wardyn K
    Endokrynol Pol; 2005; 56(1):46-54. PubMed ID: 16335674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.